

(Print or Type Responses)

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB Number:	3235-0104			
Estimated average burden nours per response 0.5				
nours per response				

#### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Statement (Month/Day/		1 0				<b>~</b> ,	•		
01/01/2016			4. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  Director Officer (give title below)		Filed(Mon	5. If Amendment, Date Original Filed(Month/Day/Year)			
					6. Individ	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
	Table I - Non-Derivative Securities Beneficially Owned						wned		
			ned I	Form: Direct D) or Indirect I)	4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Ordinary Shares with a nominal value of 0.001 GBP per share 59,2		9,269,000		I	See Note 1 (1)				
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.  Table II. Perivative Securities Repeticially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security (Instr. 4)  2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivativ Security (Instr. 4)		Price of Derivative	5. Ownership Form of Derivative Security: Direct	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
		Title	Amount	t or Number of	Security	(D) or Indirect (I) (Instr. 5)			
	O.001 GE of securities d to the clays a cur Escurities Date Exernd Expiration of Expir	D.001 GBP per 5  of securities beneficial to the collection lays a currently value Expiration Date Month/Day/Year)	Statement (Month/Day/Ye – 01/01/2016  2. Amou Beneficially own of the collection of infellings a currently valid ON Date Exercisable and Expiration Date Month/Day/Year)  3. Tit Securities Beneficially Own Date Exercisable and Expiration Date Month/Day/Year)  Expiration Date Expiration Date Securities Beneficially Own Date Expiration Date Month/Day/Year)	Table I  2. Amount of Sec Beneficially Own (Instr. 4)  2. Own (Instr. 4)  2. Amount of Sec Beneficially Own (Instr. 4)  3. Title and A Securities Date Exercisable and Expiration Date Month/Day/Year)  3. Title and A Securities Unsecurity (Instr. 4)  3. Title and A Securities Unsecurity (Instr. 4)  3. Title Amount Amount Title Amount Amount Title	Statement (Month/Day/Year)  01/01/2016  Adaptimmune  4. Relationship of Issuer  (Check a Director Officer (give title below)  2. Amount of Securities  Beneficially Owned (Instr. 4)  0.001 GBP per  59,269,000  of securities beneficially owned directly or indirectly. d to the collection of information contained in the lays a currently valid OMB control number.  e Securities Beneficially Owned (e.g., puts, calls, warrange). Date Exercisable and Expiration Date Month/Day/Year)  Oute Expiration  Title Amount or Number of  Title Amount or Number of	Adaptimmune Therapeutics  4. Relationship of Reporting Persor Issuer  (Check all applicable)  Director Officer (give title below)  Table I - Non-Derivative Securities  2. Amount of Securities Beneficially Owned (Instr. 4)  2. Amount of Securities Beneficially Owned (Instr. 5)  3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)  3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)  3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)  4. Relationship of Reporting Persor Issuer  (Check all applicable)  X 10% Own Other (specially Owned (Instr. 4)  I (Instr. 5)  3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)  I (Instr. 5)  3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)  4. Conversion or Exercise Price of Derivative Security  (Instr. 4)  Title Amount or Number of  I (Instr. 4)  Adaptimmune Therapeutics (Instr. 4)  Adaptimmune Therapeutics (Instr. 4)  Amount or Number of Issuer  (Instr. 4) Adaptimmune Therapeutics (Instr. 4)  Adaptimmune Therapeutics (Instr. 4)  A Relationship of Reporting Persor Issuer  (Instr. 4) Amount or Number of Issuer (Instr. 4)  Adaptimmune Therapeutics (Instr. 4)  A Relationship of Reporting Persor Issuer  (Instr. 4) Amount or Number of Issuer (Instr. 4)  Adaptimmune Therapeutics (Instr. 4)  A Relationship of Reporting Persor Issuer (Instr. 4)  A Relationship of Reporting Persor Issuer (Instr. 4)  A mount or Number of Issuer (Inst. 4)  A mount or Number of Issuer (Inst. 4)  B of Securities (Instr. 4)  A mount or Number of Issuer (Inst. 4)	Adaptimmune Therapeutics PLC [ADAP]  4. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  (Applicable I - Non-Derivative Securities Beneficially Owned (Instr. 4)  (Instr. 4)  (Instr. 5)  (Instr. 5)		

### **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Viswanathan Ravi 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM, MD 21093		X			

# **Signatures**

/s/ Sasha Keough, attorney-in-fact	01/04/2016
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of New Enterprise Associates 14, L.P. ("NEA 14"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.